Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dermacerium is a topical antimicrobial and wound-healing cream originally developed by Silvestre Labs and currently marketed by Cristália. It is a combination product containing silver sulfadiazine (1%) and cerium nitrate (available in 0.4% or 2.2% concentrations). Silver sulfadiazine provides broad-spectrum antimicrobial activity against Gram-positive and Gram-negative bacteria, as well as fungi, by disrupting bacterial cell membranes and binding to microbial DNA. Cerium nitrate is included to enhance the antiseptic effect and promote tissue regeneration, potentially by modulating the inflammatory response and protecting the dermal matrix in deep burns and chronic wounds. The product is primarily indicated for the prevention and treatment of infections in burns and difficult-to-heal wounds, such as diabetic foot ulcers and pressure sores.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Dermacerium.